---
title: 'Director Program Manager, Product Launch (Rare Disease) at Rezolute'
canonical: 'https://feeny.ai/job/director-program-manager-product-launch-rare-disease-rezolute-redwood-city-vn56yjrm5v16'
type: 'job'
last_seen: '2026-09-11'
---

# Director Program Manager, Product Launch (Rare Disease) at Rezolute

- **Company:** Rezolute
- **Location:** Redwood City, CA
- **Employment:** full-time
- **Work type:** onsite
- **Posted:** 2026-07-09
- **Last confirmed live:** 2026-09-11
- **Apply:** https://jobs.lever.co/rezolutebio/6f84deff-f13b-48a3-b420-0c53bf388577

## Job description

Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Our antibody therapy, RZ358 (ersodetug), is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital hyperinsulinism (cHI) and tumor hyperinsulinism (tHI)

The Director Program Manager will be a key member of the Program Management Office (PMO), responsible for Launch execution plan for the company’s first rare disease drug launch. This individual will partner closely with key stakeholders and executives from Commercial, Medical Affairs, Regulatory, Manufacturing, Supply Chain to ensure operational readiness and alignment on critical path deliverables.

This role requires a proactive leader with exceptional organizational skills, strategic thinking, and the ability to influence without direct authority in a fast-paced, evolving environment.

Location: Redwood City California (in office role with travel as needed)

## Key Responsibilities

- Leads, facilitates, coordinates and guides all aspects of the Launch Plan, working closely with the Launch Team Leader (s) to enable a program to market.
- Serve as the central point of coordination and communication to ensure the completeness and accuracy of the launch plan, its defined activities, timelines, and interdependencies.
- The role will coordinate daily between the PMO and Commercial team Chief of Staff, maintaining and aligning the launch plan. The role will closely monitor tasks and deliverables, measuring variances, outlining risks and adjusting the plan to reflect change.
- Supports cross-functional launch team meetings and ensure clear ownership, alignment, and accountability of tasks, milestones and deliverables in the Launch plan.
- Develop and maintain dashboards, reports, and KPIs to track launch readiness and identify risks, gaps, and mitigations, supporting the consolidation and input into the enterprise PMO.
- Support decision-making by ensuring timely escalation of critical issues and alignment with senior leadership.
- Drive adherence to program governance, PMO best practices, and change control processes while working within the culture of the teams and company to obtain by in.
- Build strong, trust-based relationships with functional leaders and project team members to drive collaboration and transparency.
- Provide program management support to post-launch transition activities as needed.

## Qualifications

- Bachelor’s degree required; advanced degree (MBA, MS) preferred.
- 8+ years of experience in program or project management in the biopharmaceutical industry, with at least 3 years leading or supporting a commercial launch and/or pre-commercial readiness activity in rare disease.
- Demonstrated familiarity / working knowledge of key commercialization functions in conduct of a rare disease product launch; Experience in rare disease, specialty products, or first-launch environments strongly preferred.
- Demonstrated ability to manage complex, cross-functional projects and align diverse stakeholders.
- Strong understanding of commercialization processes and timelines in the life sciences industry.
- Excellent organizational, communication, and presentation skills.
- Proficiency with project management tools (e.g., Smartsheet, MS Project) and collaboration platforms.
- PMP or related certification a plus.

## Key Competencies

- Strategic and structured problem solver with strong critical thinking.
- Highly collaborative and able to influence without authority.
- Able to thrive in ambiguity and adapt quickly to changing priorities.
- Results-driven with a sense of urgency and accountability.
- Strong interpersonal and relationship-building skills.

Rezolute (RZLT) currently anticipates the base salary for the Director Program Manager role could range from $240,000 to $290,000 and will depend, in part, on the successful candidate’s geographical location and their qualifications for the role, including education and experience. This position will also be eligible for an annual performance bonus in accordance with the terms of the applicable plan (depending, in part, on company and individual performance and at the Company’s discretion on an individual basis). The compensation described above is subject to change and could be higher or lower than the range described based on current market survey data and the qualifications, education, experience, and geographical location of the selected candidate.

Qualifying employees are eligible to participate in benefit programs such as:

- Health Insurance (Medical / Dental / Vision)
- Disability, Life & Long-Term Care Insurance
- Holiday Pay
- Tracking Free Vacation Program
- 401(k) Plan Match
- Educational Assistance Benefit
- Fitness Center Reimbursement

We are an Equal Opportunity Employer and do not discriminate against applicants due to race, ethnicity, gender, veteran status, or on the basis of disability or any other federal, state or local protected class.

## About Rezolute

## Company Overview
- **One-liner**: Rezolute is a late-stage rare disease biotechnology company developing ersodetug, a monoclonal antibody therapy for hypoglycemia caused by congenital and tumor hyperinsulinism.
- **Entity Type**: Public (Nasdaq: RZLT)
- **Headquarters**: Redwood City, California, United States (with an additional office in Louisville)
- **Founded**: Not publicly available (IPO 2012)
- **Founders**: Not publicly available

## Core Business
- **Primary industry**: Biotechnology – rare disease therapeutics
- **Target customers**: B2B – healthcare providers, patients, and payers; focuses on addressing severe unmet medical needs in hyperinsulinism
- **Mission/purpose**: Significantly improve outcomes for individuals with hypoglycemia caused by hyperinsulinism ([rezolutebio.com – About](https://rezolutebio.com/job-openings/))

## Products & Services
- **Ersodetug (lead candidate)**: An intravenously administered human monoclonal antibody that allosterically binds to the insulin receptor, down‑modulating insulin action to restore normal glucose levels. Being developed for two indications:
  - **Congenital Hyperinsulinism (sunRIZE Phase 3 study)** – completed enrollment (May 2025) with 62 participants; topline results expected December 2025.
  - **Tumor Hyperinsulinism (upLIFT Phase 3 study)** – initiated mid‑2025; FDA agreed to a single‑arm open‑label design; topline results expected second half 2026.
  - Designations: Orphan Drug (US/EU), Rare Pediatric Disease, Breakthrough Therapy (US), PRIME (EU), ILAP (UK) ([ir.rezolutebio.com – 10-K](https://ir.rezolutebio.com/sec-filings/content/0001104659-25-090848/0001104659-25-090848.pdf))

## Market Standing
- **Valuation/Market Cap**: $317.7 million (as of recent data, per LinkedIn) ([linkedin.com](https://linkedin.com/company/rezolute))
- **Key Metric (Public)**: Annual revenue of $14.1 million (likely from grants or collaboration revenue; no product revenue yet) ([linkedin.com](https://linkedin.com/company/rezolute))
- **Notable Investors/Partners**: Not publicly available – company is publicly traded and does not disclose a lead investor list. Key partners include clinical trial sites and regulatory agencies (FDA, EMA).
- **Growth Signals**:
  - Headcount: 50 employees (+2.9% YoY) ([linkedin.com](https://linkedin.com/company/rezolute))
  - Phase 3 sunRIZE study fully enrolled; topline data pending December 2025.
  - Phase 3 upLIFT study enrolling with streamlined design; data expected second half 2026.
  - FDA granted Breakthrough Therapy Designation for tumor HI in May 2025.
  - Multiple regulatory designations accelerating development pathway.

## Competitive Advantages
- **Unique mechanism**: Ersodetug acts downstream from beta cells at the insulin receptor, allowing it to potentially treat all forms of hyperinsulinism (genetic or acquired) regardless of underlying cause.
- **Dosing convenience**: Half‑life >2 weeks enables monthly intravenous administration.
- **Regulatory momentum**: Orphan Drug, Rare Pediatric Disease, Breakthrough Therapy, PRIME, and ILAP designations provide expedited review, potential priority review voucher, and closer FDA/EMA collaboration.
- **Pivotal data catalysts**: Two Phase 3 studies read out within ~12‑18 months, creating clear value inflection points.

## Strategic Focus
- Execute the two ongoing Phase 3 trials (sunRIZE in congenital HI, upLIFT in tumor HI).
- Assuming positive topline data from sunRIZE, submit a Biologics License Application (BLA) to the FDA for ersodetug in mid‑2026.
- Continue to build commercial and medical affairs infrastructure (recent job postings indicate hires in Commercial Operations, Marketing, Payer Strategy, and Supply Chain) ([rezolutebio.com – Job Openings](https://rezolutebio.com/job-openings/)).

## Why Work Here
- **Mission‑driven**: Employees work on therapies for ultra‑rare, life‑threatening conditions with high unmet medical need.
- **Benefits**: Comprehensive health/dental/vision insurance, competitive salaries, annual bonus, 401(k) with company match, tuition assistance, on‑site meals, flexible spending accounts ([rezolutebio.com – Benefits](https://rezolutebio.com/job-openings/)).
- **Work environment**: Hybrid/office policy not explicitly stated; roles are based in Redwood City (HQ) and Louisville. Recent openings include remote-friendly functions? Not confirmed.
- **Growth opportunity**: Small company (~50 people) entering late‑stage development and pre‑commercial build‑out – employees can have broad impact and career advancement.
- **Engineering culture**: For biotech, the focus is on clinical operations, regulatory, and commercial roles rather than traditional engineering. IT positions (Business System Engineer) exist.

## Sources
1. [linkedin.com – Rezolute company page](https://linkedin.com/company/rezolute)
2. [rezolutebio.com – Job Openings & Benefits](https://rezolutebio.com/job-openings/)
3. [ir.rezolutebio.com – SEC 10-K Filing (September 2025)](https://ir.rezolutebio.com/sec-filings/content/0001104659-25-090848/0001104659-25-090848.pdf)
4. [rezolutebio.com – Leadership page](https://rezolutebio.com/leadership/)

## Other roles at Rezolute

- [Sr. Medical Science Liaison](https://feeny.ai/job/sr-medical-science-liaison-rezolute-remote-p0q0xz8s2neg)
- [Senior Manager, External Supplier Operations](https://feeny.ai/job/senior-manager-external-supplier-operations-rezolute-redwood-city-pqxs0q5vsnyp) — Redwood City, CA
- [Director of Medical Affairs Operations](https://feeny.ai/job/director-of-medical-affairs-operations-rezolute-redwood-city-ck5kj9c3wbfs) — Redwood City, CA
- [Sr Director, Regulatory Affairs](https://feeny.ai/job/sr-director-regulatory-affairs-rezolute-redwood-city-wqvf8n5fvptf) — Redwood City, CA
- [Business System Engineer – Enterprise Applications](https://feeny.ai/job/business-system-engineer-enterprise-applications-rezolute-redwood-city-9pw1asb8npz9) — Redwood City, CA
- [Head of Global Product Supply](https://feeny.ai/job/head-of-global-product-supply-rezolute-redwood-city-9yv4d2b9fg0s) — Redwood City, CA
- [Sr. Director, Commercial Supply Chain](https://feeny.ai/job/sr-director-commercial-supply-chain-rezolute-redwood-city-e3ss6gz4cayw) — Redwood City, CA
- [Marketing Operations Director (Tumor HI Program)](https://feeny.ai/job/marketing-operations-director-tumor-hi-program-rezolute-redwood-city-n2vdgj2z6tjs) — Redwood City, CA